DGX rises 49.3% YTD, fueled by strong physician and hospital revenues, expanding diagnostics services, strategic acquisitions and higher earnings guidance.
Quest Diagnostics Incorporated (DGX) Presents at Jefferies Global Healthcare Conference 2026 Transcript
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
SECAUCUS, N.J., Nov. 10, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.86 per share, payable on January 27, 2027, to shareholders of record of Quest Diagnostics common stock on January 12, 2027.
SECAUCUS, N.J., Nov. 9, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the 9th Annual Evercore Healthcare Conference in Miami on Tuesday, December 1, 2026, at 2:10 p.m.
SECAUCUS, N.J., Nov. 9, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026, at 8:30 a.m.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
The Sustainable Value Strategy trailed its benchmark, the Russell 2500 Value Index, in the third quarter. New positions include Lineage, Birkenstock, Matador Resources, KBR and ICON. InterDigital, Stevanato Group and Exelixis rounded out our top contributors.
Quest Diagnostics is upgraded to a strong buy, driven by robust earnings momentum, sector resilience, and sustained outperformance versus benchmarks. DGX delivered its fourth consecutive earnings beat, with Q3 revenue up 10% YoY and EPS up 28.7%, prompting raised full-year guidance. Quest's competitive edge is reinforced by superior margins, a strong ROE above 15%, ongoing innovation, and an investment-grade balance sheet with declining leverage.
Yousif Capital Management LLC lifted its stake in Quest Diagnostics Incorporated (NYSE: DGX) by 67.3% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 25,173 shares of the medical research company's stock after purchasing an additional 10,122 shares during the quarter.